Option chain shows key data for UCB's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for UCB.

UCB (OTC:UCBJF) Stock, Option Chain

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

Stethoscope,Laying,On,Medicine,White,Pills,Money,With,Rx,Prescription

Analyst Color

Biotech

Government

Large Cap

News

Health Care

Analyst Ratings

Movers

Trading Ideas

General

ARGX

GILD

REGN

RHHBY

UCBJF

UCBJY

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Jakarta,-,Sept,12,2024:,National,Health,Service,(nhs),England,Signboard

Eurozone

AMGN

BIIB

DSNKY

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&amp;D investment and falling global competitiveness.

Pharmaceutical Firms Say UK Investment Is &#39;Unlikely&#39; Unless Payment Levy Is Adressed

Protect Your Skin

UCB&#39;s Bimzelx shows sustained efficacy in psoriasis and hidradenitis suppurativa, with high skin clearance rates and improved symptoms over long-term trials.

Europe-Based UCB&#39;s Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders

UCB SA

Comments

UCB

UCB (UCBJF) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell